Industry
Biotechnology
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Loading...
Open
9.55
Mkt cap
1.1B
Volume
734K
High
10.53
P/E Ratio
-5.33
52-wk high
16.63
Low
9.00
Div yield
N/A
52-wk low
6.88
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 5:11 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:44 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 10:42 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 3:06 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 5:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 4:14 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.